ISRCTN08435261
Completed
Not Applicable
Prostate Testing for Cancer and Treatment (ProtecT) Feasibility Study
Department of Health (UK)0 sites150 target enrollmentNovember 20, 2003
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Prostate cancer
- Sponsor
- Department of Health (UK)
- Enrollment
- 150
- Status
- Completed
- Last Updated
- 11 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Men aged 50\-69 years from specific primary care centres in the three cities were invited to attend a 30\-minute prostate check clinic appointment in which they were informed about the study and asked to consent to a prostate specific antigen (PSA) test. Men with a raised PSA (initially \=3\.0 ng/ml if 50?59 years; \=4\.0 ng/ml if 60?69 years; but changed to \=3\.0 ng/ml for all men after 1 year) were invited for biopsy. Men with confirmed localised prostate cancer were invited to participate in a randomised trial of recruitment strategies.
Exclusion Criteria
- •Men considered by the GP to be unfit for any of the potential treatments (ie those terminally ill or with serious co\-morbidity).
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
Prostate Cancer Screening with short, unenhanced Magnetic Resonance ImagingbpMRI of the prostateDRKS00031035Charité Universitätsmedizin Berlin, Klinik für Radiologie900
Recruiting
Not Applicable
Detection of clinically significant prostate cancer with MRI-TRUS fusion image-guided biopsy: comparison of the evaluation system (PI-RADS category vs. PI-RADS + US evalutaion)Suspected prostate cancerJPRN-UMIN000050631Tokai University80
Completed
Not Applicable
Prostate Cancer Screening Study of 50-75 year old men using the combination test of Circulating Tumour Cells (CTC) and Prostate-Specific Markersprostate cancerCancer - ProstateACTRN12620000793910AProf Dr Karin Ried300
Withdrawn
Not Applicable
Detection of Prostate Cancer With Non-invasive Method Based on DNA Methylation of Circulated Tumor DNA, PBMCProstate CancerProstate AdenocarcinomaProstate Cancer MetastaticNCT03494803HKGepitherapeutics
Recruiting
Not Applicable
PROstate cancer follow-up care in Secondary and Primary hEalth Care: PROSPEC study.Prostate cancer, survivorship, primary care, secondary care, follow-up, general practitioner, randomised controlled trialDutch: Prostaatcarcinoom, overlevingszorg, eerstelijnszorg, tweedelijnszorg, nazorg, huisarts, gerandomiseerd gecontroleerde trial.NL-OMON24717Antoni van Leeuwenhoek-Netherlands Cancer Institute, Amsterdam, The Netherlands390